Advertisement

Revista de Oncología

, Volume 2, Issue 3, pp 146–153 | Cite as

Expression of apoptosis-related proteins and response to chemoradiotherapy and prognosis in esophageal cancer

  • Albert Font
  • James R. RigasEmail author
  • Alan Eastman
  • Vincent A. Memoli
  • Bernard F. Cole
  • Sue Hammond
  • Rafael Rosell
Originales
  • 25 Downloads

Abstract

Purpose

Defects in the apoptotic pathway confer insensitiviry to the cytotoxic effects of chemotherapy and hence represent an important distal mechanism for the development of chemoresistance. In this study, we sought to obtain results on which to base clinical hypotheses about this mechanism. The aim of this study was to analyze the correlation of the expression of three of these apoptotic molecules, Bc1-2, Bax and Bc1-X, with chemoradiotherapy response and clinical outcome in patients with esophageal tumors.

Patients and methods

Tumor biopsy specimens from 42 patients were assessed by immunohistochemistry for expression of Bc1-2, Bax and Bc1-X proteins. The expression of these proteins was correlated with response to chemoradiotherapy in 24 patients.

Results

The overall expression of Bc1-2, Bax and Bc1-X was 29%, 68% and 88%, respectively. Bax expression was lower in lymph-node-positive tumors (p = 0.01). Probability of response to chemoradiotherapy was higher in Bax-negative tumors than in Bax-positive tumors (80% vs 35%, p = 0.1). In addition, 62% of patients with low Bc1-X expression (< 50% stained cells) showed response to chemoradiotherapy, as opposed to only 33% of patients with higher Bc1-X expression (p = 0.2). Patients with low Bc1-X expression showed a significantly better prognosis than those with high Bc1-X expression (p =0.02), and a tendency towards higher survival was detected in Bc1-2 positive patients.

Conclusion

The correlation detected between Bax and Bc1-X expression and response to chemoradiotherapy suggests that screening for these apoptosisrelated proteins could be useful in determining patients who would benefit from chemoradiotherapy. However, further investigation is warranted to elucidate the potential role of Bax in taxane-treated patients. Clearly, since high Bc1-X expression conferred poor survival in our study, it could be a useful prognostic marker in esophageal cancer.

Key words

Esophageal cancer Chemoradiotherapy Apoptosis-related proteins Prognostic marker 

Expresión de proteinas implicadas en la apoptosis y su relación con la respuesta a la quimiorradioterapia y al pronóstico en el cáncer de esófago

Resumen

Propósito

Las alteraciones en el patrón de apoptosis confieren insensibilidad a los efectos citotóxicos de la quimioterapia y representan un importante mecanismo en el desarrollo de quimiorresistencia. Este estudio se ha realizado para analizar el papel que desempefian los mecanismos de apoptosis en la práctica clínica. El objetivo del estudio fue establecer la correlación entre la expresión de Bcl-2, Bax y Bcl-X con la respuesta a la quimiorradioterapia y el pronósitco en pacientes con cancer de esófago.

Pacientes y métodos

Se han analizado, mediante inmunohistoquímica, las biopsias de 42 pacientes para determinar la expresión de las proteínas Bcl-2, Bax y Bcl-X. En 24 de estos pacientes la expresión de estas proteínas se correlacionó con la respuesta a quimiorradioterapia.

Resultados

La expresión de Bcl-2, Bax y Bcl-X se detectó en un 29, un 68 y un 88% de los tumores, respectivamente. La expresión de Bax fue inferior en tumores con afectación de los ganglios linfáticos (p = 0,01). La probabilidad de respuesta a la quimiorradioterapia fue superior en los tumores Bax negativos respecto a los positivos para dicha proteína (80 y 35%, respectivamente; p = 0,1). El 62% de pacientes con expresión baja de Bc1-X (< 50% de células teñidas) respondieron al tratamiento con quimiorradioterapia; por el contrario, sólo un 33% de los pacientes con expresión elevada de Bcl-X respondieron al tratamiento (p = 0,2). En los pacientes con expresión baja de Bcl-X el pronóstico fue significativamente mejor que en los pacientes con expresión elevada (p = 0,02); así mismo, los pacientes con tumores con expresión de Bcl-2 demostraron una tendencia a una supervivencia mejor.

Conclusiones

La relación entre la expresión de Bax y Bcl-X y la respuesta a la quimiorradioterapia sugiere que el estudio de las proteínas relacionadas con la apoptosis podría ser de utilidad para deter — minar qué pacientes pueden beneficiarse de dicho tratamiento. Se requieren más estudios para definir el papel de la proteína Bax en los pacientes tratados con taxanos. En nuestro estudio, la expresión elevada de Bcl-X se correlacionó con un peor pronóstico y, por tanto, podría ser un marcador pronóstico en el cáncer de esófago.

Palabras clave

Cáncer de esófago Quimiorradioterapia Proteínas relacionadas con la apoptosis Marcador pronóstico 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Forastiere AA, Heitmiller RF and Kleinberg L. Multimo-dality therapy for esophageal cancer. Chest 1997; 112 (Supl): 195–200.CrossRefGoogle Scholar
  2. 2.
    Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462–467.CrossRefPubMedGoogle Scholar
  3. 3.
    Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantinon G, Elias D et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161–167.CrossRefPubMedGoogle Scholar
  4. 4.
    Krajewski S, Thor AD, Edgerton SM, Moore DH, Krajewska TM, Reed JC. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin Cancer Res 1997; 3: 199–208.PubMedGoogle Scholar
  5. 5.
    Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56: 2178–2184.PubMedGoogle Scholar
  6. 6.
    Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329: 690–694.CrossRefPubMedGoogle Scholar
  7. 7.
    Bonetti A, Zaninelli M, Leone R, Cetto GL, Pelosi G, Biolo S et al. Bcl-2 but not p53 expression is associated with resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 1998; 4: 2331–2336.PubMedGoogle Scholar
  8. 8.
    Gallo O, Boddi V, Calzolari A, Simonetti L, Trovati M, Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin Cancer Res 1996; 2: 261–267.PubMedGoogle Scholar
  9. 9.
    Borre M, Stausbol-Gron B, Nerstrom B, Overgaard J. Immunohistochemical BCL-2 and Ki-67 expression predict survival in prostate cancer patients followed expectantly. Prostate Cancer and Prostatic Diseases 1998; 5: 268–275.CrossRefGoogle Scholar
  10. 10.
    Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471–4478.PubMedGoogle Scholar
  11. 11.
    Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 1998; 16: 2583–2590.PubMedGoogle Scholar
  12. 12.
    Ohbu M, Saegusa M, Kobayashi N, Tsukamoto H, Mieno H, Kakita A et al. Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis. Cancer 1997; 79: 1287–1293.CrossRefPubMedGoogle Scholar
  13. 13.
    Puglisi F, Di Loreto C, Panizzo R, Avellini C, Fongione S, Cacitti V et al. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996; 49: 456–459.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Patel DD, Bhatavdekar JM, Chikhlikar PR, Patel YV, Shah NG, Ghosh N et al. Clinical significance of p53, nm23 and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach. J Surg Oncol 1997; 65: 111–116.CrossRefPubMedGoogle Scholar
  15. 15.
    Sarbia M, Stahl M, Fink U, Willers R, Seeber S, Gabbert HE. Expression of apoptosis-regulating proteins and outcome of esophageal cancer patients treated by combined therapy modalities. Clin Cancer Res 1998; 4: 2991–2997.PubMedGoogle Scholar
  16. 16.
    Urba S, Orringer M, Turrisi A, Whyte R, Iannettoni M, Forastiere A. A randomized trial comparing surgery to preoperative concomitant chemoradiation plus surgery in patients with resectable esophageal cancer: updated analysis. Proc Am Soc Clin Oncol 1997; 16: 277.Google Scholar
  17. 17.
    Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593–1598.CrossRefPubMedGoogle Scholar
  18. 18.
    Torzewski M, Sarbia M, Heep H, Dutkowski P, Willers R, Gabbert HE. Expression of Bcl-XL, an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Clin Cancer Res 1998; 4: 577–583.PubMedGoogle Scholar
  19. 19.
    Ofner D, Riehemann K, Maier H, Reidmann B, Nehoda H, Totsch M et al. Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumor stage and patient survival. Br J Cancer 1995; 72: 981–985CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Sarbia M, Bittinger F, Porschen R, Verreet P, Dutkowski P, Willers R et al. Bcl-2 expression and prognosis in squamous cell carcinomas of the esophagus. Int J Cancer 1996; 69: 324–328.CrossRefPubMedGoogle Scholar
  21. 21.
    Sarbia M, Bittinger F, Grabellus F, Verreet P, Dutkowski P, Willers R et al. Expression of bax, a proapoptotic member of the bcl-2 family, in esophageal squamous cell carcinoma. Int J Cancer 1997; 73: 508–513.CrossRefPubMedGoogle Scholar
  22. 22.
    Apolinario RM, Van der Valk P, De Jong JS, Deville W, Van Ark-Otte J, Dingemans AMC et al. Prognostic value of the expression of p53, bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non-small cell lung cancer. J Clin Oncol 1997; 15: 2456–2466.PubMedGoogle Scholar
  23. 23.
    Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81: 151–157.PubMedGoogle Scholar
  24. 24.
    Tu Y, Renner S, Xu FH, Fleishman A, Taylor J, Weisz J et al. BCL-X expression in multiple myeloma: Possible indicator of chemoresistance. Cancer Res 1998; 58: 256–262.PubMedGoogle Scholar
  25. 25.
    Strobel T, Kraeft SK, Chen LB, Cannistra SA. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res 1998; 58: 4776–4781.PubMedGoogle Scholar
  26. 26.
    Strobel T, Tai YT, Korsmeyer S, Cannistra SA. BAD partly reverses paclitaxel resistance in human ovarian cancer cell. Oncogene 1998; 17: 2419–2427.CrossRefPubMedGoogle Scholar
  27. 27.
    Escuin D, Rosell R. The anti-apoptosis survivin gene and its role in human cancer: an overview. Clinical Lung Cancer 1999; 1: 138–143.CrossRefPubMedGoogle Scholar
  28. 28.
    Singh KK, Russell J, Scigala B, Zhang Y, Williams J, Keshar KF. Mitochondrial DNA determines the cellular response to cancer therapeutic agents. Oncogene 1999; 18: 6641–6646.CrossRefPubMedGoogle Scholar
  29. 29.
    Murphy KM, Satreips UN, Lock RB. Bax membrane insertion during Fas (CD95)-induced apoptosis precedes cytochrome c release and is inhibited by Bcl-2. Oncogene 1999; 18: 5991–5999.CrossRefPubMedGoogle Scholar
  30. 30.
    Bairey O, Zimra Y, Shaklai M, Okon E, Rabizadeh E. Bcl-2, Bcl-X, Bax and Bak expression in short- and long-lived patients with diffuse large B-cell lymphomas. Clin Cancer Res 1999; 5: 2860–2866.PubMedGoogle Scholar

Copyright information

© FESEO 2000

Authors and Affiliations

  • Albert Font
    • 1
  • James R. Rigas
    • 2
    Email author
  • Alan Eastman
    • 3
  • Vincent A. Memoli
    • 4
  • Bernard F. Cole
    • 5
  • Sue Hammond
    • 6
  • Rafael Rosell
    • 1
  1. 1.Department of Medical OncologyHospital Germans Trias i PujolBadalonaSpain
  2. 2.Departments of Medical OncologyDartmouth Hitchcock Medical CenterLebanon
  3. 3.Departments of Molecular TherapeuticsDartmouth Hitchcock Medical CenterLebanon
  4. 4.Departments of PathologyDartmouth Hitchcock Medical CenterLebanon
  5. 5.Departments of BiostatisticsDartmouth Hitchcock Medical CenterLebanon
  6. 6.Departments of Data CoordinationDartmouth Hitchcock Medical CenterLebanon

Personalised recommendations